Dovato vs. Biktarvy

• Are Dovato and Biktarvy the Same Thing?
• What Are Possible Side Effects of Dovato?
• What Are Possible Side Effects of Biktarvy?
• What Is Dovato?
• What Is Biktarvy?
• What Drugs Interact with Dovato?
• What Drugs Interact with Biktarvy?
• How Should Dovato Be Taken?
• How Should Biktarvy Be Taken?

Dovato (dolutegravir and lamivudine) and Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) are combinations of integrase strand transfer inhibitors (INSTIs) and nucleoside analogue reverse transcriptase inhibitors (NRTIs) used as complete regimens to treat human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of either drug.

Side effects of Dovato and Biktarvy that are similar include headache, diarrhea, nausea, insomnia, fatigue, and dizziness.

Side effects of Biktarvy that are different from Dovato include abnormal dreams.

Both Dovato and Biktarvy may interact with other antiretroviral medications, dofetilide, metformin, anticonvulsants, St. John's wort, certain antacids, and oral calcium and iron supplements (including multivitamins containing calcium or iron).

Dovato may also interact with rifampin, cation-containing laxatives, sucralfate, buffered medications, and sorbitol.

Biktarvy may also interact with antimycobacterials, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs).

Common side effects of Dovato include:

• headache,
• diarrhea,
• nausea,
• insomnia,
• fatigue, and
• dizziness

Common side effects of Biktarvy include:

• diarrhea,
• nausea,
• headache,
• fatigue,
• abnormal dreams,
• dizziness, and
• insomnia

Dovato (dolutegravir and lamivudine) is a combination of an integrase strand transfer inhibitor (INSTI) and a nucleoside analogue reverse transcriptase inhibitor (NRTI) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of Dovato.

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a three-drug combination of a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and two HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

Dovato may interact with other antiretroviral drugs for the treatment of HIV-1 infection, dofetilide, metformin, anticonvulsants, rifampin, St. John's wort, cation-containing antacids or laxatives, sucralfate, buffered medications, oral calcium and iron supplements (including multivitamins containing calcium or iron), and sorbitol.

Biktarvy may interact with other antiretroviral medications, dofetilide, anticonvulsants, antimycobacterials, St John's wort, antacids containing aluminum or magnesium, supplements containing calcium or iron, metformin, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Biktarvy; it is unknown how it would affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Biktarvy during pregnancy. Because of the potential for HIV transmission, breastfeeding while using Biktarvy is not recommended.

The dose of Dovato is one tablet taken orally once daily with or without food.

Biktarvy is a three-drug fixed dose combination product containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of Biktarvy is one tablet taken once daily with or without food.